HopeStage
Back to all studies
CompletedNCT00584519

Metabolic and cardiovascular health in schizophrenia with overweight

About this titleRead the official source — NCT00584519
Observational studyAges 18+
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2007
Recruitment status
Completed
Enrollment listed in the registry
430
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type
Other organization
Study type
Observational
Intervention type
Other
Locations
Not clearly listed
Age range
Over 18 Years
Official registry ID
NCT00584519
Official title
Show the full official title

Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight (CRESSOB)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies